Last reviewed · How we verify
Ibrutinib combined with As2O3
Ibrutinib inhibits Bruton's tyrosine kinase (BTK) to block B-cell proliferation, while arsenic trioxide (As2O3) induces apoptosis and differentiation in leukemic cells through multiple pathways.
Ibrutinib inhibits Bruton's tyrosine kinase (BTK) to block B-cell proliferation, while arsenic trioxide (As2O3) induces apoptosis and differentiation in leukemic cells through multiple pathways. Used for Acute leukemia (investigational combination therapy), B-cell malignancies with arsenic sensitization.
At a glance
| Generic name | Ibrutinib combined with As2O3 |
|---|---|
| Also known as | Ibrutinib combined with arsenic trioxide |
| Sponsor | Peking University People's Hospital |
| Drug class | BTK inhibitor combined with arsenic compound |
| Target | BTK (Bruton's tyrosine kinase); As2O3 has multiple targets including PML-RARA fusion protein and mitochondrial pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ibrutinib is a BTK inhibitor that disrupts B-cell receptor signaling, preventing malignant B-cell survival and proliferation. Arsenic trioxide acts as a dual-mechanism agent that promotes apoptosis and differentiation of leukemic blasts, particularly in acute promyelocytic leukemia. The combination leverages complementary mechanisms to enhance anti-leukemic activity.
Approved indications
- Acute leukemia (investigational combination therapy)
- B-cell malignancies with arsenic sensitization
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Neutropenia
- Arsenic-related hepatotoxicity
- QT prolongation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibrutinib combined with As2O3 CI brief — competitive landscape report
- Ibrutinib combined with As2O3 updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI